In our clinical study, JAK1 inhibition combined with either IDO1 or PI3Kδ inhibition did not lead to enhanced immune activation as evidenced by a lack of CD8+ T-effector cell infiltration into the tumor microenvironment. The gene discussed is CD8A; the disease is neoplasm.